83004-13-1

Usage

Uses

Used in Pharmaceutical Industry:
2-bromo-6-ethyl-pyridine is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with specific therapeutic properties, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 2-bromo-6-ethyl-pyridine serves as an essential building block for the creation of novel agrochemicals. Its incorporation into these compounds can enhance their effectiveness in pest control and crop protection, thereby supporting sustainable agriculture.
Used in Organic Synthesis:
2-bromo-6-ethyl-pyridine is utilized as a versatile building block in organic synthesis for the production of various functional groups. Its reactivity and structural features make it a valuable component in the synthesis of complex organic molecules, driving innovation in the field of organic chemistry.

Upstream product

• 5315-25-3 2-bromo-6-methylpyridine 
• 74-88-4 methyl iodide 
• 21717-29-3 2-amino-6-ethylpyridine 
• 109-04-6 2-bromo-pyridine 
• 74-85-1 ethene 

Downstream Products

• 59146-66-6 6-ethyl-2-cyanopyridine 
• 1283601-75-1 bis(3,5-dimethylphenyl)(6-ethyl-2-pyridyl)phosphine 
• 1380072-43-4 6-ethyl-2-(3-cyanophenylethynyl)pyridine 
• 521917-53-3 2-bromo-6-ethyl-pyridine 1-oxide 
• 521917-55-5 2-Bromo-6-ethyl-pyridin-4-ylamine 

Relevant academic research and scientific papers

IRAK4 INHIBITING AGENTS

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease.

IRAK4 INHIBITING AGENTS

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

Rare-earth-catalyzed C-H bond addition of pyridines to olefins

An efficient and general protocol for the ortho-alkylation of pyridines via C-H addition to olefins has been developed, using cationic half-sandwich rare-earth catalysts, which provides an atom-economical method for the synthesis of alkylated pyridine der

MACROCYCLIC INHIBITORS OF JAK

The present invention relates to the use of novel macrocyclic compounds of Formula I, wherein the variables Q, Q1, Q2, Q3, and Q4 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.

3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES

The present invention provides 3-indazoyl-4-pyridylisothiazoles or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and methods of using the same, as well as processes for preparing the same, and intermediates thereof.

Heterocyclic compounds as inhibitors of factor VIIa

The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel heterocyclic compounds, or a stereoisomer or pharmaceutically acceptable salt, solvate, or prodrug form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

Preparation of Tricarbonyl(η6-pyridine)chromium(0) Complexes

The synthesis of tricarbonyl(η6-pyridine)chromium(0) complexes is accomplished via complexation of 2-silylpyridines with subsequent fluoride ion-mediated desilylation under mild conditions.The tricarbonylchromium(0) complexes of pyridine, 2-methylpyridine, 3-methylpyridine, 2-ethylpyridine, 2-(but-3-enyl)pyridine and 2-(6-trimethylsilylpyridyl)-1,3-dioxolane are prepared.Deprotonation (lithium diisopropylamide) and methylation (methyl iodide) of tricarbonyl(η6-pyridine)chromium(0) converts it cleanly to tricarbonyl(η6-2-methylpyridine)chromium(0).